Tvardi Therapeutics (TVRD) Cash & Current Investments: 2013-2017
Historic Cash & Current Investments for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $103.0 million.
- Tvardi Therapeutics' Cash & Current Investments rose 44.19% to $103.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $310.5 million, marking a year-over-year decrease of 13.55%. This contributed to the annual value of $58.3 million for FY2016, which is 45.40% down from last year.
- Per Tvardi Therapeutics' latest filing, its Cash & Current Investments stood at $103.0 million for Q3 2017, which was down 8.41% from $112.4 million recorded in Q2 2017.
- In the past 5 years, Tvardi Therapeutics' Cash & Current Investments ranged from a high of $112.4 million in Q2 2017 and a low of $690,000 during Q1 2013.
- In the last 3 years, Tvardi Therapeutics' Cash & Current Investments had a median value of $84.8 million in 2016 and averaged $79.2 million.
- Per our database at Business Quant, Tvardi Therapeutics' Cash & Current Investments surged by 9,615.65% in 2014 and then crashed by 61.75% in 2017.
- Over the past 5 years, Tvardi Therapeutics' Cash & Current Investments (Quarterly) stood at $12.4 million in 2013, then skyrocketed by 326.18% to $52.7 million in 2014, then spiked by 102.69% to $106.7 million in 2015, then slumped by 45.40% to $58.3 million in 2016, then spiked by 44.19% to $103.0 million in 2017.
- Its Cash & Current Investments was $103.0 million in Q3 2017, compared to $112.4 million in Q2 2017 and $36.8 million in Q1 2017.